Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1957 1
1982 3
1983 1
1985 1
1986 2
1987 2
1988 4
1990 1
1991 1
1992 2
1993 2
1994 2
1995 3
1996 2
1997 1
1998 1
1999 1
2000 4
2001 5
2003 1
2004 1
2005 7
2006 2
2007 3
2008 5
2009 6
2010 9
2011 8
2012 10
2013 6
2014 6
2015 4
2016 6
2017 4
2018 7
2019 4
2020 4
2021 5
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. Le DT, et al. Among authors: fisher ga. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. N Engl J Med. 2015. PMID: 26028255 Free PMC article. Clinical Trial.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Le DT, et al. Among authors: fisher ga. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8. Science. 2017. PMID: 28596308 Free PMC article. Clinical Trial.
Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Kunz PL, et al. Among authors: fisher ga. J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19. J Clin Oncol. 2023. PMID: 36260828 Free PMC article. Clinical Trial.
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. Sikic BI, et al. Among authors: fisher ga. J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811285 Free PMC article. Clinical Trial.
The reversal of multidrug resistance.
Fisher GA, Lum BL, Sikic BI. Fisher GA, et al. Cancer Treat Res. 1995;78:45-70. doi: 10.1007/978-1-4615-2007-8_3. Cancer Treat Res. 1995. PMID: 8595147 Review. No abstract available.
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
King DA, Smith AR, Pineda G, Nakano M, Michelini F, Goedegebuure SP, Thyparambil S, Liao WL, McCormick A, Ju J, Cioffi M, Zhang X, Hundal J, Griffith M, Grandori C, Pollastro M, Rosati R, Margossian A, Chatterjee P, Ainge T, Flory M, Ocampo P, Chen LM, Poultsides GA, Baron AD, Chang DT, Herman JM, Gillanders WE, Park H, Hoos WA, Nichols M, Fisher GA, Kuo CJ. King DA, et al. Among authors: fisher ga. JCO Precis Oncol. 2023 Apr;7:e2100489. doi: 10.1200/PO.21.00489. JCO Precis Oncol. 2023. PMID: 37079860 Free PMC article. No abstract available.
Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.
Stockton S, Catalano P, Cohen SJ, Burtness BA, Mitchell EP, Dotan E, Lubner SJ, Kumar P, Mulcahy MF, Fisher GA, Crandall TL, Benson A. Stockton S, et al. Among authors: fisher ga. Oncologist. 2023 Sep 7;28(9):827-e822. doi: 10.1093/oncolo/oyad096. Oncologist. 2023. PMID: 37104870 Free PMC article. Clinical Trial.
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS. Strosberg JR, et al. Among authors: fisher ga. World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450. World J Gastroenterol. 2015. PMID: 25741154 Free PMC article. Review.
133 results